HALOZYME THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HALOZYME THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $121.70M | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | $65.32M | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | $55.22M | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | $25.35M | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | $53.67M | Feb 23, 2021 |
| FY2020 | Sep 30, 2019 | $46.23M | Feb 23, 2021 |
| FY2020 | Jun 30, 2019 | $39.15M | Feb 23, 2021 |
| FY2020 | Mar 31, 2019 | $56.95M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $60.23M | Feb 24, 2020 |
| FY2019 | Sep 30, 2018 | $25.56M | Feb 24, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.02B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $829.25M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $660.12M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $443.31M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $267.59M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $195.99M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $151.86M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $316.61M | Feb 24, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $6.18M | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | $3.48M | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | $597.0K | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | $2.36M | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | $6.01M | Feb 23, 2021 |
| FY2020 | Sep 30, 2019 | $6.87M | Feb 23, 2021 |
| FY2020 | Jun 30, 2019 | $3.88M | Feb 23, 2021 |
| FY2020 | Mar 31, 2019 | $3.74M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $5.06M | Feb 24, 2020 |
| FY2019 | Sep 30, 2018 | $5.64M | Feb 24, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $316.89M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $444.09M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $281.59M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $202.13M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $402.71M | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $73.16M | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | $36.21M | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | $25.82M | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | ($6.10M) | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | ($34.40M) | Feb 23, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $469.01M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $551.48M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $337.57M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $267.53M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $275.90M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $144.26M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($67.61M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($69.33M) | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $81.00M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | ($83.21M) | Feb 21, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $79.05M | Feb 18, 2025 |
| FY2024 | Dec 31, 2023 | $76.36M | Feb 18, 2025 |
| FY2024 | Dec 31, 2022 | $66.61M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $35.67M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $34.24M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $140.80M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $150.25M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $150.64M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $150.84M | Feb 21, 2019 |
| FY2017 | Dec 31, 2015 | $93.24M | Feb 20, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $207.09M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $154.34M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $149.18M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $143.53M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $50.32M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $45.74M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $77.25M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $60.80M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $53.82M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $45.85M | Feb 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $651.56M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $479.06M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $388.57M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $240.11M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $299.44M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $55.45M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($85.42M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($49.50M) | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $134.05M | Feb 24, 2020 |
| FY2016 | Dec 31, 2016 | ($50.38M) | Feb 28, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.97M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $10.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $15.29M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $4.81M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.46M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $2.50M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $4.04M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $4.66M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $1.35M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $3.14M | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.53B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.06B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.73B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.84B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.10B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $579.92M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $565.87M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $440.25M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $519.95M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $261.52M | Feb 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.48B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.70B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.65B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.67B | Feb 20, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.81M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $363.82M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $83.81M | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | $169.80M | Feb 17, 2026 |
| FY2024 | Dec 31, 2021 | $196.95M | Feb 18, 2025 |
| FY2023 | Dec 31, 2020 | $151.05M | Feb 20, 2024 |
| FY2022 | Dec 31, 2019 | $91.77M | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $248.89M | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | $208.37M | Feb 23, 2021 |
| FY2019 | Dec 31, 2016 | ($32.48M) | Feb 24, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $580.36M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $416.82M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $416.82M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $409.05M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Feb 21, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.79M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $359.87M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $90.55M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $143.22M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | ($58.91M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | ($474.59M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | ($603.68M) | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | ($531.44M) | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | ($522.37M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($585.34M) | Feb 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.82M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $115.85M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $118.37M | Feb 17, 2026 |
| FY2023 | Dec 31, 2022 | $234.20M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $118.72M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $147.70M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $120.18M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $57.94M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $168.74M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $66.76M | Feb 20, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.14B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.51B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.50B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.51B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $787.26M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $383.05M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $34.87M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $125.14M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $199.23M | Feb 20, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 23, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 23, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 117.78M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 123.14M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 126.77M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 135.15M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | 137.50M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 135.03M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 136.71M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | 144.73M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | 142.79M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | 129.50M | Feb 20, 2018 |